Funding for this research was provided by:
PhD Faculty Growth SUPRA scholarship jointly funded by Swinburne University of Technology and Baker Heart and Diabetes Institute
Faculty of Pharmacy- Alexandria University
Monash University Scholarships
Baker Bright Sparks Scholarship
Australian Research Council (DE200100985)
RMIT University VC Fellowship
National Heart Foundation Future Leader Fellowship (101932)
Baker Institute Fellowship
National Health and Medical Research Council Investigator L3 Fellowship (GNT1174098)
Received: 25 June 2022
Accepted: 23 September 2022
First Online: 15 October 2022
: Not applicable.
: All authors gave their consent for publication.
: XW and KP are inventors on patents describing activated-platelet-targeting single chain antibodies. KP is inventor and chief medical officer of NIRTEK. The other authors declare no conflict of interest.